drugset

drugset / Trial / NCT00141180

CP-481,715 Nickel Allergy Study.

NCT00141180 ↗

Phase 1 Completed 48 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Timeline

Start: 2003-09
Primary completion: —
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CP-481,715	Unknown	—	—

Indications